Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zendium is a science-led oral care brand, originally developed in Scandinavia and now owned by Unilever, that focuses on strengthening the mouth's natural defenses. Unlike traditional toothpastes that use antibacterial agents to kill bacteria, Zendium utilizes a unique combination of enzymes and proteins—including amyloglucosidase, glucose oxidase, and lactoperoxidase—to promote a healthy oral microbiome. The brand's products are clinically proven to increase good bacteria while reducing bad bacteria associated with gum problems and sensitivity. Zendium is widely recognized for its mild formulations, making it suitable for individuals with delicate mouths or those prone to mouth ulcers. The brand represents a significant application of biotechnology in consumer healthcare, leveraging the lactoperoxidase system to maintain oral physiological balance.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zendium.